Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study
- 30 July 2013
- journal article
- clinical trial
- Published by Springer Nature in International Journal of Hematology
- Vol. 98 (3) , 323-330
Abstract
Eltrombopag is an oral, nonpeptide, thrombopoietin receptor agonist approved for treatment of chronic immune thrombocytopenia (ITP). The safety, tolerability, and efficacy of eltrombopag for up to 3 years were evaluated in 19 Japanese patients with chronic ITP who had completed a prior 6-month study. Patients received eltrombopag once daily at the last dosage received in the prior study (12.5, 25, or 50 mg). Dose adjustments and treatment interruptions were permitted to maintain platelet counts of 50,000–200,000/μL. Primary evaluations were safety and tolerability of long-term eltrombopag treatment. The median duration of exposure was 27.5 months (range, 9.9–32.3). Adverse events were similar to those reported with short-term use of eltrombopag, and none led to treatment discontinuation. Nine serious adverse events were reported. Median platelet counts began to increase after 1 week of treatment and remained above 50,000/μL for most assessments. Bleeding episodes decreased from 63 % at baseline to 21 % after 2 weeks of treatment and remained below baseline for all assessments. Of 15 patients receiving concomitant baseline ITP medications, 10 permanently discontinued or achieved a sustained reduction of at least one treatment without requiring rescue treatment. Long-term treatment with eltrombopag was safe, well tolerated, and effective in Japanese patients with chronic ITP.Keywords
This publication has 25 references indexed in Scilit:
- A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopeniaJournal of Thrombosis and Haemostasis, 2012
- Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic PurpuraThe Journal of Clinical Pharmacology, 2011
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Pharmacokinetics and Pharmacodynamics of Eltrombopag in Healthy Japanese MalesRinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2011
- Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agentsBlood, 2010
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- EltrombopagDrugs, 2009
- Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpuraBlood, 2008
- Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and managementThrombosis and Haemostasis, 2008
- Treatment of chronic immune thrombocytopenic purpura: the patients’ perspectiveEuropean Journal of Haematology, 2007